• Philippe Généreux, John G Webb, Lars G Svensson, Susheel K Kodali, Lowell F Satler, William F Fearon, Charles J Davidson, Andrew C Eisenhauer, Raj R Makkar, Geoffrey W Bergman, Vasilis Babaliaros, Joseph E Bavaria, Omaida C Velazquez, Mathew R Williams, Irene Hueter, Ke Xu, Martin B Leon, and PARTNER Trial Investigators.
• Columbia University Medical Center/New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York 10032, USA.
• J. Am. Coll. Cardiol. 2012 Sep 18;60(12):1043-52.

ObjectivesThis study sought to identify incidence, predictors, and impact of vascular complications (VC) after transfemoral (TF) transcatheter aortic valve replacement (TAVR).BackgroundVC after TF-TAVR are frequent and may be associated with unfavorable prognosis.MethodsFrom the randomized controlled PARTNER (Placement of AoRTic TraNscathetER Valve) trial, a total of 419 patients (177 from cohort B [inoperable] and 242 from cohort A [operable high-risk]) were randomly assigned to TF-TAVR and actually received the designated treatment. First-generation Edwards-Sapien valves and delivery systems were used, via a 22- or 24-F sheath. The 30-day rates of major and minor VC (modified Valve Academic Research Consortium definitions), predictors, and effect on 1-year mortality were assessed.ResultsSixty-four patients (15.3%) had major VC and 50 patients (11.9%) had minor VC within 30 days of the procedure. Among patients with major VC, vascular dissection (62.8%), perforation (31.3%), and access-site hematoma (22.9%) were the most frequent modes of presentation. Major VC, but not minor VC, were associated with significantly higher 30-day rates of major bleeding, transfusions, and renal failure requiring dialysis, and with a significantly higher rate of 30-day and 1-year mortality. The only identifiable independent predictor of major VC was female gender (hazard ratio [HR]: 2.31 [95% confidence interval (CI): 1.08 to 4.98], p = 0.03). Major VC (HR: 2.31 [95% CI: 1.20 to 4.43], p = 0.012), and renal disease at baseline (HR: 2.26 [95% CI: 1.34 to 3.81], p = 0.002) were identified as independent predictors of 1-year mortality.ConclusionsMajor VC were frequent after TF-TAVR in the PARTNER trial using first-generation devices and were associated with high mortality. However, the incidence and impact of major VC on 1-year mortality decreased with lower-risk populations.Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

30 keywords...

hide…